[Are there differences among anti-TNFα biological drugs?]

Reumatismo. 2005;57(4 Suppl):1-2. doi: 10.4081/reumatismo.2005.4s.1.
[Article in Italian]

Abstract

Objective: To provide an analysis and a guide tool in using TNFα-antagonists in the current clinical practice.

Methods: Review of the literature on the differences among the three TNFα-antagonists in terms of molecular structure, mechanism of action, pharmacokinetics, effects on the immune and neuroendocrine systems, and therapeutic indications.

Results and conclusions: Unfortunately, results of direct comparison studies are lacking. One could obviate this problem by performing statistical-mathematical extrapolations, but there are very few and very small-sized published experimental evidences.

Publication types

  • English Abstract
  • Introductory Journal Article

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / pharmacology
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Receptors, Tumor Necrosis Factor, Type II / antagonists & inhibitors
  • Rheumatic Diseases / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type II
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept